GSA Capital Partners’s Immunogen Inc IMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-17,856
| Closed | -$529K | – | 2068 |
|
|
2023
Q4 | $529K | Sell |
17,856
-96,299
| -84% | -$1.92M | 0.04% | 759 |
|
|
2023
Q3 | $1.81M | Buy |
114,155
+78,791
| +223% | +$1.31M | 0.16% | 135 |
|
|
2023
Q2 | $667K | Buy |
35,364
+5,564
| +19% | +$65.7K | 0.07% | 559 |
|
|
2023
Q1 | $114K | Buy |
+29,800
| New | +$127K | 0.01% | 1343 |
|
|
2022
Q1 | – | Sell |
-37,682
| Closed | -$280K | – | 1933 |
|
|
2021
Q4 | $280K | Buy |
37,682
+10,442
| +38% | +$64.9K | 0.04% | 983 |
|
|
2021
Q3 | $154K | Buy |
+27,240
| New | +$157K | 0.02% | 1280 |
|
|
2020
Q2 | – | Sell |
-112,009
| Closed | -$382K | – | 1223 |
|
|
2020
Q1 | $382K | Buy |
112,009
+91,557
| +448% | +$400K | 0.1% | 318 |
|
|
2019
Q4 | $104K | Buy |
+20,452
| New | +$69.4K | 0.01% | 1337 |
|
|
2019
Q1 | – | Sell |
-56,800
| Closed | -$273K | – | 1759 |
|
|
2018
Q4 | $273K | Buy |
+56,800
| New | +$345K | 0.03% | 884 |
|
|
2018
Q3 | – | Sell |
-116,400
| Closed | -$1.13M | – | 1976 |
|
|
2018
Q2 | $1.13M | Sell |
116,400
-102,700
| -47% | -$1.08M | 0.06% | 678 |
|
|
2018
Q1 | $2.31M | Sell |
219,100
-51,334
| -19% | -$507K | 0.12% | 213 |
|
|
2017
Q4 | $1.73M | Buy |
270,434
+150,610
| +126% | +$929K | 0.11% | 297 |
|
|
2017
Q3 | $917K | Sell |
119,824
-18,702
| -14% | -$124K | 0.06% | 584 |
|
|
2017
Q2 | $985K | Buy |
138,526
+53,000
| +62% | +$243K | 0.06% | 553 |
|
|
2017
Q1 | $331K | Buy |
85,526
+47,400
| +124% | +$138K | 0.02% | 1325 |
|
|
2016
Q4 | $78K | Buy |
+38,126
| New | +$76.5K | ﹤0.01% | 1690 |
|
Other funds holding IMGN
GSA Capital Partners's IMGN Position: Q1 2024 in Review
GSA Capital Partners sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 17,856 shares — an estimated $529K sold.
GSA Capital Partners first reported a position in IMGN in Q4 2016 and held it in 16 quarters. The position peaked at $2.31M in Q1 2018. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.
- GSA Capital Partners reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
- GSA Capital Partners sold 17,856 Immunogen Inc shares in Q1 2024, an estimated $529K.
- GSA Capital Partners first reported a position in Immunogen Inc in Q4 2016 and held it in 16 quarters.
- GSA Capital Partners's Immunogen Inc position peaked at $2.31M in Q1 2018.
- 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.
Based on GSA Capital Partners's 13F filing for Q1 2024, filed 3 May 2024.